Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India

June 2, 2020 – Wetteren, Belgium – Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that it has completed the acquisition of Granules OmniChem Private Limited, purchasing the remaining 50 percent ownership interest from its joint venture partner, Granules India Limited. The transaction, announced in August 2019, strengthens Aji Bio-Pharma’s commitment to providing its clients accessibility to a reliable and simplified CDMO supply chain across all sites globally.

Now doing business as Ajinomoto Bio-Pharma Services India (“Aji Bio-Pharma India”), the organization is fully integrated into Aji Bio-Pharma’s global operations. The Visakhapatnam, India site, which was designed, constructed and is managed based on the Aji Bio-Pharma Belgian sites’ GMP operating standards and quality systems, has successfully supported a number of the world’s leading biopharmaceutical companies since its formation in 2011.

“The addition of Aji Bio-Pharma India is an integral extension of Aji Bio-Pharma’s dedication to its customers to be a leading global and quality-driven CDMO with comprehensive service offerings,” said David Enloe, President and CEO, Ajinomoto Bio-Pharma Services. “We are excited to officially welcome the Aji Bio-Pharma India team to our global family, and we look forward to providing a further streamlined experience for our clients as they continue to deepen their partnerships with us on essential programs in their product pipeline.”

“We are very pleased to be a part of a worldwide network committed to simplifying our clients’ supply chain,” said K.V.V. Raju, CEO, Ajinomoto Bio-Pharma India Pvt. Ltd. He further added, “As a fully integrated member of Aji Bio-Pharma, we are committed to advancing Aji Bio-Pharma’s Vision Statement of being a leading, trusted, innovative partner to our clients and our people.”

味の素バイオファーマサービスについて

味の素バイオファーマサービスは、ベルギー、米国、日本、インドに拠点を置く完全統合型の受託開発・製造機関（CDMO）であり、低分子・高分子の原薬および中間体に対し、包括的な開発、cGMP準拠の製造、無菌充填・包装サービスを提供しています。 味の素バイオファーマ・サービスは、Corynex®タンパク質発現技術、オリゴヌクレオチド合成、抗体薬物複合体（ADC）、高活性原薬（HPAPI）、生体触媒、連続フロー製造など、前臨床およびパイロットプログラムから商業生産規模に至るまで、幅広い革新的なプラットフォームと能力を提供しています。 味の素バイオファーマ・サービスは、お客様のニーズに応えるため、高水準の品質とサービスの提供に尽力しています。詳細はこちら：www.AjiBio-Pharma.com